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Abstract We describe a patient with dystonia and psychotic
symptoms treated with standard doses of antipsychotics, who
developed neuroleptic malignant syndrome (NMS). A 16-
year-old male with a history of misuse of dextromethorphan
and pseudoephedrine for recreational purpose presented with
dystonia and a psychotic episode. Following continuous treat-
ment with olanzapine (10 mg/day), repeated injections of
levomepromazine (37.5 mg/day), and a single injection of
haloperidol (2.5 mg), the patient developed NMS. Muscular
rigidity, fever (up to 41 °C), hypotension (100/70 mmHg),
tachycardia (120 beats per minute), tachypnea (26 breaths per
minute), elevated leukocyte count (up to 16.6×103/μL), and
elevated serum creatinine phosphokinase (CPK) (up to 15,
255 U/L) were observed. A diagnosis of NMS was made
according to the DSM-IV TR criteria. Genotyping revealed
that he was homozygous for a non-functional CYP2D6*4
allele. The case highlights the importance of therapeutic drug
monitoring in identification and differentiation of drug-
induced effects in psychiatric disorder to prevent NMS and
its complications. In addition, genotyping of CYP2D6 might
be considered in patients with symptoms suggestive of drug
toxicity who are treated with neuroleptics metabolized via the
CYP2D6 pathway, as carriage of one or more non-functional
alleles may increase the risk for adverse reactions, such as
NMS.
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Abbreviations
BUN Blood urea nitrogen
CPK Serum creatinine phosphokinase
DSM-IV
TR
Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition, Text Revision
EEG Electroencephalography
ICU Intensive care unit
NMS Neuroleptic malignant syndrome
PCR Polymerase chain reaction
SCC Creatinine
TDM Therapeutic drug monitoring
WBC Leukocyte count
Introduction
The use of atypical antipsychotic has increased rapidly in
recent years in pediatric populations worldwide [1]. Neuro-
leptic malignant syndrome (NMS) is a rare but potentially
fatal complication of treatment with antipsychotics. Clinical
features of NMS include muscle rigidity, hyperpyrexia, auto-
nomic instability, mental status changes, and evidence of
muscle catabolism [2]. One of the hypotheses regarding its
etiology postulates that susceptibility to NMS may be associ-
ated with variation in genes that code for metabolic enzymes
[7]. We report on a pediatric patient who developed NMS
while being treated with standard doses of antipsychotics due
to an acute psychotic episode. Clinical observation suggested
drug toxicity due to impaired drugmetabolism. Genotyping of
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the CYP2D6 gene confirmed the carriage of two dysfunction-
al alleles.
Case report
In September 2009, a 16-year-old male (weight: 65.5 kg,
height: 1.83 m, BMI=19.6 kg/m2) was admitted to a pediatric
neurology unit due to dystonia. A month before, the patient
became withdrawn and developed insomnia and twisting
movements of the left extremities. These symptoms began
after a 1-month period of using medication containing dextro-
methorphan and pseudoephedrine for recreational purpose.
Upon admission to the pediatric neurology unit, he was well
oriented and followed instructions. Neurological examination
showed no alteration except for sustained twisting of the left
extremities. Results of laboratory tests, electroencephalogra-
phy (EEG), and computed tomography of the head and neck
were normal. During hospitalization his mental status deteri-
orated. He became confused and illogical. The consulting
psychiatrist diagnosed a psychotic episode and transferred
the patient to the adolescent inpatient psychiatric unit.
At the time of this transfer, the patient was awake and
revealed delusional thoughts and hallucinations. Treatment
with orally administered olanzapine (10 mg/day) and loraze-
pam (as required) with intramuscular injections of first-
generation antipsychotic medication—levomepromazine
(25 mg/day)—was initiated. The next day, levomepromazine
was increased to 37.5 mg/day. During the course of treatment,
dystonic movement worsened. Opisthotonic trunk extension,
intermittent, sustained extension movements of the arms, and
incomprehensible screaming were observed. The patient had
no verbal communication with the medical staff, was agitated,
unable to sleep, and refused to eat and drink. Intravenous
fluids were administered for dehydration. In 2 weeks of treat-
ment, he became drowsy with decreased physical activity.
Due to recurrent episodes of agitation, the patient received
1–3 mg/day of lorazepam. An episode of aggression towards
medical staff required one intramuscular injection with halo-
peridol (2.5 mg). The timeline of presented symptoms and
administered medications is displayed in Fig. 1. At the 16th
day of treatment with antipsychotics, the patient was trans-
ferred to the University Child Psychiatry Department.
At the time of this transfer, the patient was unconscious and
showed muscular rigidity and extrapyramidal symptoms. Fe-
ver (up to 41 °C), hypotension (100/70 mmHg), tachycardia
(120 beats per minute), and tachypnea (26 breaths per minute)
were noted. Laboratory analysis revealed a leukocyte count
(WBC) of 13.40×103/μL, serum creatinine phosphokinase
(CPK) level of 639 U/L, and normal liver and renal function
tests.
On the following day, the patient became diaphoretic, with
a Glasgow Coma Scale of 7 points (range 3–15 points) indi-
cating a state of coma. CPK increased to 2,458 U/L, WBC to
16.6×103/μL, creatinine (SCC) to 1.70mg/dL, and blood urea
nitrogen (BUN) to 79.0 mg/dL. The patient was transferred to
an intensive care unit (ICU), intubated and mechanically
ventilated because of respiratory insufficiency. Generalized
tonic–clonic seizures were observed. Acyclovir was adminis-
tered for potential herpes encephalitis and dantrolene to










































































Fig. 1 Timeline of presented symptoms and administered medication prior to admission to the intensive care unit
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counter potential NMS. Electrocardiogram revealed elevation
of the ST segment with T wave inversion. Elevated troponin
levels and myoglobin detected in urine suggested myocardial
injury. An echocardiogram showed left ventricular
hypokinesis. Serum CPK levels continued to rise over the
following 6 days and reached a peak of 15,255 U/L. BUN
and SCC also increased for 3 days, up to 79.6 and 2.1 mg/dL,
respectively. Organic pathology of the brain was ruled out after
repeatedly normal magnetic resonance images and cerebrospi-
nal fluid examination (glucose concentration 70.0 mg/dL,
protein concentration 34 mg/dL, and an absence of cells).
Polymerase chain reaction (PCR) ruled out herpes simplex
virus infection, and acyclovir was discontinued. Six weeks
after the last administration of neuroleptics, urine toxicology
was done. The presence of haloperidol was detected, but not
olanzapine. The presence of levomepromazine was not mea-
sured. There was no test performed to measure any plasma
drug concentration. Real-time PCR showed that the genotype
of CYP2D6 was *4/*4. These findings indicated lack of
CYP2D6 activity.
As other conditions were excluded, the diagnosis of NMS
was made based on symptoms of muscle rigidity, elevated
temperature, and leukocytosis. After 10 weeks of hospitaliza-
tion in the ICU, the patient was readmitted to the psychiatric
unit. His weight had decreased to 41 kg (BMI=12.2 kg/m2). At
the time of readmission, he was agitated and visually halluci-
nating. Extrapyramidal symptomswere present. Disturbance of
mental status fluctuated during the course of the day with
worseness of agitation in the nights. The diagnosis of delirium
was stated. Secondary generalized tonic–clonic seizures were
noted every second day. Agitation was treated with
ziprasidone, and gabapentin was introduced for seizures. Dur-
ing the subsequent 6-month hospitalization, the patient's con-
dition gradually improved, and he gained 12.5 kg (weight:
53.5 kg, height: 1.83 m, BMI=16.0 kg/m2). In June 2010, he
was discharged from inpatient center with diagnosis of
schizophreniform disorder complicated by neuroleptic malig-
nant syndrome according to DSM-IV TR criteria. He remained
under regular review in the outpatient psychiatric clinic. Con-
trol EEGs performed 6 and 12 weeks after the above episode
were normal. Ziprasidone and gabapentin were gradually with-
drawn, and no other medications were required. In September
2010, he went back to school. However, due to learning
difficulties, he had to repeat the class. After 2.5 years of
outpatient follow-up, he still shows persistent mild memory
and concentration impairment and emotional lability. There has
been no further evidence of psychotic symptoms or seizures.
Discussion
This is the first report of a pediatric patient with NMS and
confirmed CYP2D6 deficiency. Symptoms presented by the
patients such as fever, rigidity, tachycardia, leukocytosis, dia-
phoresis, abnormal blood pressure, tachypnea, altered mental
status, and elevated CK level are consistent with clinical
presentations of other patients with NMS [11]. Remarkably,
the development of NMS was preceded by catatonic symp-
toms such as mutism, refusal of food and fluid intake, and
decreased and excesive motor activity. There are reports sug-
gesting that neuroleptic-induced catationa may be a stage
progressing to NMS [9]. In the presented case, catatonic
symptoms occurred after introduction of neutroleptics, and
further treatment even worsen the mental state of the patient
(Fig. 1).
This case illustrates a multifactorial cause of NMS. The
primary risk factors are probable disproportionally high
drug concentrations - which were unfortunetely not mea-
sured - and toxicity resulting from repeated administration
of oral and intramuscular medication in a patient with
dysfunctional metabolic pathways. This patient received
repeated daily doses of olanzapine. The role of olanzapine
and its combination with levomepromazine in the devel-
opment of NMS has been previously described [5, 8]. The
plasma level of olanzapine should not have exceed thera-
peutic levels as it is mainly metabolized by CYP1A2 and to
a lesser extent by CYP2D6. However, the clinical presen-
tation, with the lack of improvement and sedation on
adequate doses of medications combined with worseness
of catatonia, suggests drug toxicity. Metabolism of
levomepromazine and haloperidol is catalyzed by
CYP2D6 and if given to the patient with lack activity of
this enzyme might have induced adverse effects even on
standard doses [3]. Furthermore, nonfunctional alleles of
CYP2D6 have been suggested to affect vulnerability to
NMS in Japanese population [6]. Other factors such as
dehydration, malnutrition, and severe clinical presentation
with agitation may also contribute to the development of
NMS. Initial symptoms of the patient might be also related
to the abuse of dextromethorphan- and pseudoepedrine-
containing remedies as both medications are metabolized
by CYP2D6 and known to cause dystonia and psychotic
symptoms [10].
Our report highlights the need for therapeutic drug monitor-
ing (TDM) [4]. TDM is economically reasonable and can detect
different pharmacokinetic problems, not limited to CYP poly-
morphisms. Unfortunately, in Poland, TDM of neuroleptics was
not implemented in the clinical routine and even if recommend-
ed remains unavailable in psychiatric centers. Described patient
had several indications for measuring plasma concentration of
medication such as possible medication-related onset of symp-
toms, adverse effects on standard doses ofmedication, suspected
impaired drug metabolism, and being an adolescent patient.
Plasma levels of drugs involved in this case would have been
helpful to evaluate the origin of symptoms, modify the treat-
ment, and avoid dramatic complication.
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